Acute Myocardial Infarction Articles & Analysis
12 news found
The PACIFIC-STROKE2 and PACIFIC-AMI3 Phase IIb trials compared the safety and efficacy of asundexian with placebo in patients following acute non-cardioembolic ischemic stroke or acute myocardial infarction (AMI), respectively. ...
ByBayer AG
The depiction of 68Ga-FAPI-46 PET signal after acute anterior myocardial infarction was selected as SNMMI’s 2022 Image of the ...
BySOFIE
Miracor Medical SA (Miracor Medical) today announced the first patient enrolled in the PICSO-AMI-V study to evaluate the benefits of PiCSO® (Pressure-controlled intermittent Coronary Sinus Occlusion) therapy as an adjunct to conventional primary percutaneous coronary intervention (PCI) for patients presenting with inferior ST-Elevation Myocardial Infarction ...
The code provides clear reimbursement for the study procedure performed for both the treatment and control arms for the ongoing cell therapy pivotal trials in two cardiovascular indications: the CardiAMP Cell Therapy Heart Failure Trial (NCT02438306) and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial (NCT03455725). “This most recent action by CMS further ...
BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. The CardiAMP Cell Therapy Heart Failure Trial has been supported financially by the ...
In a highly anticipated document published online yesterday in Circulation and the Journal of the American College of Cardiology, the Joint Committee on Clinical Practice Guidelines for the American College of Cardiology & American Heart Association released new clinical practice guidelines for managing patients with Acute and Stable chest pain. Backed by strong clinical ...
ByElucid
Rosenfield is the Section Head for Vascular Medicine and Intervention and chairs the Acute Myocardial Infarction (STEMI) Committee for the Cardiac Catheterization Laboratory at Massachusetts General Hospital. ...
The primary safety endpoint, defined as absence of periprocedural major vascular complications, major bleeding, acute kidney injury, or death within one month, was met in 96% of patients. ...
Patients with heart failure as a consequence of previous myocardial infarction are a large and currently underserved patient population, due to the lack of regenerative treatment options. ...
The study is designed to prove superiority of PiCSO used as an adjunct to PCI over a conventional strategy of PCI alone, in reducing infarct size measured by CMR at 5 days. Secondary efficacy endpoints include MVO and cardiac function (EF, LVESV, LVEDV) at 5 days and 6 months. ...
All of these important advancements have underscored that, as in the treatment of acute myocardial infarctions, improved mechanical solutions to physically open the blocked brain artery will continue to offer clear advantages for improved patient outcomes,” said Imperative Care co-founder L. ...
PiCSO therapy accelerates the microcirculatory recovery resulting in significantly lower IMR (Index of Microcirculatory Resistance) at 24-48 hours when compared to controls leading to overall infarct size reduction. “These clinical results are very encouraging. ...